ArticleBMC cancer2026
MYC amplification is common in cancer of the stomach and gastroesophageal junction, correlates with male sex and reduced response to neoadjuvant therapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to demonstrate that MYC amplification in adenocarcinomas of the stomach (GC) and gastroesophageal junction (GEJ) is of tumor biological significance and exhibits intratumoral heterogeneity.
methodsMYC amplification was analyzed by fluorescence in situ hybridization using whole mount tissue sections obtained from resection specimens of 460 chemotherapy naive (surgery only) and 122 neoadjuvantly treated GC-GEJs. The extent of intratumoral heterogeneity was quantified and a MYC score was established.
resultsThe number of MYC-amplified tumor cells varied largely ranging from few scattered single cells (< 20 per high power field) up to all tumor cells. MYC score 1 was found in 276 cases (47.4%). Split by cohorts, 199 (43.3%) tumors of the chemotherapy naïve (surgery only) and 77 (63.1%) tumors of the neoadjuvant cohort were sorted into the category MYC Score 1. These tumors were frequently located in the gastroesophageal junction, showed non-diffuse differentiation according to Lauren, and favored male sex. Additionally, correlations with higher T- and N category were observed. Overall survival and tumor-specific survival correlated negatively with the MYC score.
conclusionsMYC amplification is common in GC-GEJ, most often heterogeneously distributed, and associated with reduced therapy response. Most interestingly, MYC amplification is far more common in men, providing evidence for sex-specific disease mechanisms, and in tumors that show little response to neoadjuvant chemotherapy, suggesting a link to therapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.